STRR reports Q1 results today with short sellers barely present — but insiders have been quietly accumulating stock ahead of the print.
The insider angle is unusually clean for a micro-cap. Through late March, multiple board members and a divisional CEO made open-market purchases at prices between $9.82 and $10.61. Director Todd Fruhbeis bought on five separate occasions across three days. The net insider position over the trailing 90 days is a positive 7,765 shares at a total cost of roughly $80,000 — modest in dollar terms, but the clustering of purchases from several distinct insiders close to today's event is notable for a company this size. The largest single holder, Chairman and CEO Jeffrey Eberwein, already controls 28% of outstanding shares, giving management a concentrated stake in whatever the numbers deliver.
Short interest is too thin to be a meaningful signal here. SI amounts to just 0.13% of the free float — effectively no organised bearish positioning. The borrow market reflects this: cost to borrow runs near 3.9% and availability in the lending pool is extremely wide, meaning there is no squeeze dynamic to consider. Short interest also dropped sharply in late April, falling from around 15,000 shares in early April to roughly 4,600 shares after April 24 — the move looks mechanical rather than sentiment-driven, and with a short score of 28, ORTEX ranks the stock well below average for short pressure.
The valuation picture is genuinely inexpensive. The stock trades at a P/E near 9.6x on an EV/EBITDA of roughly 3.2x, and at a price-to-book of just 0.52x. Both the P/E and EV/EBITDA multiples have compressed modestly over the past 30 days, tightening the valuation case further. On the income side, forward estimates point to revenue around $237 million and net income near $1.3 million, with operating cash flow above $7 million — a meaningful delta between earnings and cash generation that will attract scrutiny. The stock closed Friday at $9.46, down slightly on the week and broadly flat over the past month.
With no analyst coverage and no options market to read, today's print is a referendum on whether Star Equity's underlying operating businesses — primarily healthcare construction and staffing — are generating the revenue quality and margin consistency that would justify the insider accumulation at prices above current levels.
See the live data behind this article on ORTEX.
Open STRR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
